Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF EBITDA Margin
EBITDA as a percentage of revenue.
Profound Medical Corp.NASDAQ: PROF
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -148.4%
EBITDA Margin was -148.4% in Q1 FY2026, up 271.4 pp from a year earlier. On a trailing-twelve-month basis it was -200.6%, up 96.6 pp year over year. Over 3 fiscal years it widened by 145.4 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -102.8% for the fiscal year ending Dec 2026, up from -252.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -148.4%-27.0 pp QoQ
- Last fiscal yearDec 2025
- -252.8%-1.1 pp YoY
- LTMMar 2026
- -200.6%+96.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -252.8%
- Year-over-year change
- -1.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -252.8% | -1.1pp |
| FY2024 | 2024-12-31 | -251.7% | +120.3pp |
| FY2023 | 2023-12-31 | -372.0% | +26.2pp |
| FY2022 | 2022-12-31 | -398.2% | +18.6pp |
| FY2021 | 2021-12-31 | -416.8% | — |
EBITDA Margin vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 EBITDA Margin of -200.6% is the 7th highest of the 11 companies compared; the peer median is -77.0%.
- Its year-over-year change of +96.6 pp is the 2nd highest of 11, against a peer median of +2.6 pp.
- Over three fiscal years its change of +145.4 pp compares with a peer median of +13.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 58.8% | +150.4 pp | -4.3 pp | |
| LTM Mar 2026 | -17.0% | +26.6 pp | +30.8 pp | |
| LTM Mar 2026 | -40.4% | -29.4 pp | +75.4 pp | |
| LTM Mar 2026 | -45.4% | +91.4 pp | +1621.5 pp | |
| LTM Mar 2026 | -46.7% | +22.3 pp | +304.0 pp | |
| LTM Mar 2026 | -107.3% | -9.8 pp | -72.7 pp | |
| LTM Mar 2026 | -200.6% | +96.6 pp | +145.4 pp | |
| LTM Dec 2025 | -376.3% | +15.0 pp | +506.1 pp | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -5021.0% | -1760.3 pp | -3924.4 pp |
| LTM Mar 2026 | -8872.8% | -9159.7 pp | -2521.0 pp | |
| LTM Mar 2026 | -17902.8% | -12192.4 pp | -11194.0 pp | |
| Peer median (excluding PROF) | -77.0% | +2.6 pp | +13.3 pp | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.87M | 6.68M | 7.2M | 10.17M | 16.38M |
| Cost of Revenue | 3.92M | 3.66M | 2.82M | 3.47M | 4.79M |
| Gross Profit | 2.95M | 3.02M | 4.38M | 6.7M | 11.59M |
| Gross Margin | 43.0% | 45.2% | 60.9% | 65.9% | 70.8% |
| Research & Development | 15.28M | 14.69M | 14.38M | 16.15M | 20.96M |
| Selling, General & Admin | 17.97M | 17.93M | 18.62M | 22.02M | 32.61M |
| Operating Expenses | 33.24M | 35.15M | 33M | 38.17M | 53.57M |
| Depreciation & Amortization | 1.88M | 1.6M | 1.15M | 891.06K | 569.8K |
| EBITDA | (28.65M) | (26.6M) | (26.78M) | (25.59M) | (41.41M) |
| EBITDA Margin | -416.8% | -398.2% | -372.0% | -251.7% | -252.8% |
| Operating Income | (30.29M) | (32.13M) | (28.62M) | (31.47M) | (41.98M) |
| Operating Margin | -440.7% | -480.9% | -397.5% | -309.6% | -256.3% |
| Interest Income | 203.2K | 1.05M | 1.64M | 1.37M | 1.09M |
| Interest Expense | 66.41K | 167.11K | 770K | 0 | 0 |
| Other Income / Expenses | (303K) | 3.74M | (81K) | 4.99M | (1.08M) |
| Income Before Tax | (30.59M) | (28.38M) | (28.7M) | (26.48M) | (43.06M) |
| Pre-Tax Margin | -445.1% | -424.8% | -398.6% | -260.5% | -262.9% |
| Income Tax Expense | 105K | 287K | (128K) | (1.9K) | 256.41K |
| Net Income | (30.7M) | (28.67M) | (28.57M) | (26.48M) | (43.32M) |
| Net Margin | -446.7% | -429.1% | -396.8% | -260.4% | -264.4% |
| EPS (Basic) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| EPS (Diluted) | (1.50) | (1.38) | (1.35) | (1.07) | (1.43) |
| Weighted Avg Shares | 20.46M | 20.83M | 21.18M | 24.77M | 30.23M |
| Weighted Avg Shares (Diluted) | 20.47M | 20.83M | 21.18M | 24.77M | 30.23M |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.